DOP79 Biomarkers for IBD using OLINK Proteomics inflammation panel: Preliminary results from the COLLIBRI consortium

Padhmanand Sudhakar(KU Leuven), Jonas Halfvarson(Örebro University), Ryan C. Ungaro(Feinstein Institute for Medical Research), Bram Verstockt(Universitair Ziekenhuis Leuven), Heath Guay(AbbVie (United States)), Konrad Aden(Hochschule für Angewandte Wissenschaften Kiel), Benita Salomon(Örebro University), Koji Komori(Aichi Cancer Center), Mark S. Silverberg(Sinai Health System), G D’Haens(Amsterdam University Medical Centers), Séverine Vermeire(KU Leuven)
Journal of Crohn s and Colitis
January 1, 2022
10.1093/ecco-jcc/jjab232.118
Cited by 4

Related Papers

A Genome-Wide Association Study Identifies <i>IL23R</i> as an Inflammatory Bowel Disease Gene
|Science|2006|3k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
A decrease of the butyrate-producing species <i>Roseburia hominis</i> and <i>Faecalibacterium prausnitzii</i> defines dysbiosis in patients with ulcerative colitis
|Gut|2013|1.9k
ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications
|Journal of Crohn s and Colitis|2018|1.8k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k